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microRNATICs are characterized by their ability to self-renew, differentiate and initiate tumor formation. miRNAs are
small noncoding RNAs that bind to mRNAs resulting in regulation of gene expression and biological functions.
The role of miRNAs and TICs in cancer progression led us to hypothesize that miRNAs may regulate genes in-
volved in TIC maintenance. Using whole genome miRNA and mRNA expression proﬁling of TICs from primary
prostate cancer cells, we identiﬁed a set of up-regulated miRNAs and a set of genes down-regulated in PSs.
Inhibition of these miRNAs results in a decrease of prostatosphere formation and an increase in target gene
expression. This study uses genome-wide miRNA proﬁling to analyze expression in TICs. We connect aber-
rant miRNA expression and deregulated gene expression in TICs. These ﬁndings can contribute to a better un-
derstanding of the molecular mechanisms governing TIC development/maintenance and the role that
miRNAs have in the fundamental biology of TICs.
© 2011 Elsevier Inc. All rights reserved.1. Introduction
Prostate cancer is the most frequently diagnosed cancer in men
and in 2010 it was estimated that in the United States alone there
would be approximately 32,050 deaths [1]. Consequently, this places
prostate cancer second among the top ten cancer types leading to
death [1]. Although the development of androgen ablation therapy
has proven effective in regression of prostate tumors, for a large ma-
jority of patient's, remission is only temporary as these patients often
develop resistance, leading to androgen-independent cancer that is
lethal.
Tumor-initiating cells (TICs) are hypothesized to drive tumor ini-
tiation, drug resistance and metastasis. TICs have been identiﬁed
and isolated in a variety of solid cancer models including breast [2],nuity Pathway Analysis; KO,
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rights reserved.colon [3], pancreas [4], brain [5] and prostate [6,7]. TICs are a sub-
population of cells within a tumor that are capable of both self-
renewal and differentiation and are capable of recapitulating the orig-
inal tumor from which they were isolated (reviewed in [8]). The
mechanism(s) governing TIC self-renewal and differentiation are
under intense investigation and are critical to our understanding of
TIC biology and their role in tumorigenesis.
MicroRNAs (miRNAs) represent a class of small noncoding RNAs
(20–22 nt-long) that result from the processing of primary transcripts
by the RNase III enzymes Drosha and Dicer. miRNAs bind to their cor-
responding mRNA resulting in mRNA degradation or translational in-
hibition, thereby regulating gene expression [9–12]. miRNAs have
been previously shown to regulate a variety of biological functions in-
cluding tissue differentiation and maintenance, disease such as type 2
diabetes and carcinogenesis [11–14]. Furthermore, miRNAs have
the capability to maintain and promote a differentiated state in em-
bryonic stem cells (ESCs) as they target transcription factors needed
to maintain ESC pluripotency [12]. Although the role of miRNAs in
both embryonic and adult stem cells is currently under investigation,
there is increasing evidence suggesting that miRNAs play a key role in
TIC regulation as well. This includes miRNA regulation of genes in-
volved in both self-renewal and differentiation of TICs such as Notch
(Notch1), Oct4 (POU5F1), Sox2, Bmi-1 (BMI1) and KLF4 [9,12,14].
Dysregulation of these regulatory networks can result in aberrant
cell cycle progression, differentiation and cell survival. These speciﬁc
biological processes have been shown to regulate TIC maintenance.
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metastasis [14] and miRNAs have been shown to regulate genes and
biological processes involved in TIC maintenance [12,14], we sought
to investigate whether miRNAs have a role in the regulation and
maintenance of gene expression in prostate TICs. Our laboratory has
established a sphere formation assay for primary patient cells to cul-
ture a population representative of the TIC population termed prosta-
tospheres (PSs) that can increase tumor initiation [15]. We used this
sphere formation assay to isolate PSs and subsequently used a
miRNA proﬁling approach to identify upregulated miRNAs in PSs
compared to the adherent parent population. With a whole genome
microarray platform, we compared the gene expression pattern of
the PSs to the adherent parent population to see if we could identify
downregulated genes that are direct gene targets of the identiﬁed
upregulated miRNAs. In this study, we identify a subset of upregu-
lated miRNAs within the TIC population, as well as three speciﬁc
genes, BCL9, TXNIP and SOX4, which are downregulated in the TIC
population which we hypothesize to be a result of aberrant miRNA
expression. Furthermore, we demonstrate that inhibition of the iden-
tiﬁed miRNAs results in the inhibition of prostate sphere formation,
suggesting that these speciﬁc miRNAs may function in the self-
renewal of TICs.
The use of miRNA proﬁling to identify speciﬁc aberrant miRNAs
within the TIC population, we believe, is an invaluable tool. We are
able to identify speciﬁc miRNAs that function in the self-renewing
ability of this unique and lethal population. The identiﬁcation of aber-
rant miRNAs and the detection of their gene targets may lead to a bet-
ter understanding of the underlying molecular mechanism(s) that
govern TIC maintenance.
2. Materials and methods
2.1. Cell lines
Primary human prostate cancer cells (PCSC1, PCSC2, and PCSC3)
were obtained from Celprogen (San Pedro, CA) and maintained
in the recommended prostate cancer stem cell media provided by
Celprogen. Prostatospheres from PCSC1, PCSC2 and PCSC3 cells were
isolated as previously described [15].
2.2. Microarray analysis
RNA was isolated from prostatospheres and labeled as previously
described [7], with the following modiﬁcations. Reverse transcriptase
was heat inactivated at 65 °C for 10 min followed by RNaseA RNA
degradation at room temperature for 30 min. Universal Reference
RNA (Stratagene, La Jolla, CA) was labeled with Cy3-dUTP and exper-
imental samples were labeled with Cy5-dUTP. Samples were hybrid-
ized to an Agilent whole genome gene expression array following
manufacturer's directions. Arrays were scanned using a GenePix
4000B scanner (Molecular Devices, Sunnyvale, CA) and analyzed
using NCI mAdb (https://madb.nci.nih.gov/index.shtml), a microarray
and data analysis system for NCI/CCR scientists/collaborators.
2.3. Quantitative real-time RT-PCR
Total RNA was isolated from both adherent cells and prostato-
spheres using the miRNeasy mini kit according to the manufacturer's
instructions (Qiagen). miRNeasy kit allows the puriﬁcation of miRNA
along with mRNA and other noncoding RNAs. miScript reverse tran-
scription kit was used for the efﬁcient reverse transcription of miR-
NAs and other noncoding RNAs into cDNA in a single step. miRNA
was quantiﬁed with miScript PCR system (Qiagen) using ABI
7900HT, according to the manufacturer's protocol. Expression was
quantiﬁed in triplicate of each sample and endogenous controls. To
evaluate differences in miRNA expression, a relative quantiﬁcation(ΔΔCT) method was chosen where the expression of the miRNA tar-
get is standardized by a non-regulated small non-coding RNA used as
reference. U6B (RNU6) and SNORA73A were used as endogenous
controls because the level of these small RNA remains essentially con-
stant from sample to sample. miRNA assays corresponding to miR-
Base v14 were used for the genomewide proﬁling (Qiagen).
For mRNA detection, cDNA was prepared using the SuperScript®
III First-Strand Synthesis System (Invitrogen Corporation, Carlsbad,
CA) and quantitative real time polymerase chain reaction (qRT-PCR)
analysis was performed using a StepOne Real-time PCR machine
(Applied Biosystems, Foster City, CA) with TaqMan Gene Expression
Assay reagents and probes (Applied Biosystems). The following
TaqMan based human probes were used: BCL9 (Hs00180272_m1),
TXNIP (Hs00197750_m1), SOX4 (Hs00268388_s1), 18S rRNA
(Hs99999901_s1). Relative fold induction of mRNA was compared
between the adherent population and prostatospheres using the
relative quantiﬁcation (ΔΔCT) method, and 18S rRNA was used as a
normalization control. All experiments were performed in triplicate
and repeated three independent times.
2.4. Western blots
Cells were lysed in radioimmunoprecipitation assay (RIPA) buffer
and 50 μg were loaded on a 4–20% gradient gel (Invitrogen). Gels
were subjected to semi-dry transfer to PVDF membrane, blocked in
5% non-fat milk and incubated overnight at 4 °C with the following
primary antibodies at a 1:200–1:500 dilution in PBST: α-BCL9
(Santa-Cruz), α-TXNIP (Santa-Cruz), α-Sox4 (Santa-Cruz) and α-
Actin was used as a loading control. IRDye (LI-COR, Lincoln, NE) sec-
ondary antibodies were used and the blots were imaged on Licor's
Odyssey Infrared Scanner. Quantiﬁcation analysis was performed
using ImageJ Software provided by the National Institute of Health
(http://rsb.info.nih.gov/ij/).
2.5. miR inhibition studies
PCSC3 cells were seeded in SCMKO media and transfected using
HiPerFect Transfection Reagent per manufacturer's recommendations
with miScript miRNA Inhibitors (Qiagen). After 7 days in culture,
PCSC3 cells were scanned for sphere formation and counted using
GelCount (Oxford Optronix). For miR inhibition qRT-PCR analysis
studies, cells were transfected and after 7 days, cells were harvested.
RNA was isolated using Qiagen's miRNeasy mini kit and the miScript
reverse transcription kit was used for reverse transcription of
miRNAs. miRNA expression was quantiﬁed in triplicate of each sam-
ple and U6B was used as an endogenous control. Statistical analysis
was performed using GraphPad Prism's one-way ANOVA analysis
with a Dunnett's post-test (p-valueb0.05).
2.6. Oncomine database analysis
The Oncomine database, version 4.4, (http://www.oncomine.org)
was queried to assess gene expression levels in prostate primary
tumor samples as well as metastatic specimens.
3. Results
3.1. Identiﬁcation of upregulated miRNAs in prostatospheres
Our laboratory has recently reported the isolation of a small pop-
ulation of cells termed prostatospheres (PSs) from primary prostate
cancer cells using a sphere formation assay [15]. These primary pros-
tate cancer stem cells were isolated from patients presenting
with recurrent prostate tumors that had previously undergone che-
motherapy and radiation therapy prior to tumor extraction [15]. Our
Table 2
Upregulated miRs and their associated cancers.
A literature search was performed for the upregulated miRs identiﬁed in our miRNA
proﬁling assay. Table 2 states the upregulated miRs and their previously identiﬁed as-
sociation with various cancer types.
microRNA PCSC1 PCSC2 PCSC3
25⁎ 2.64 0.79 1.05
130a 1.49 1.33 2.55
425 1.34 1.89 2.14
30e 28.79 1.16 2.76
30d 28.96 1.28 2.92
221 29.01 2.47 3.60
194 1.49 1.66 1.60
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initiation studies that the PSs isolated from this assay are representa-
tive of the TIC population [15]. These PSs signiﬁcantly express stem
cell markers in comparison to the adherent parental line, are highly
tumorigenic and have a gene signature that correlates with prostate
cancer status and progression [15]. As previously stated, there is over-
whelming evidence supporting a role for miRs in the initiation and
progression of cancer (reviewed in [11]). For this reason, we sought
to identify upregulated miRs in prostatospheres that may function
as key regulators of the TIC population. We ﬁrst isolated PSs from pri-
mary prostate cancer cells (PCSC1, PCSC2 and PCSC3) using the
sphere formation assay and extracted RNA from PSs and adherent
non-tumor initiating cell populations. We used a novel two-step
strategy to proﬁle global changes in miRNA expression in prostato-
spheres (manuscript in preparation). In the ﬁrst step, cDNA was
prepared from individual samples of adherent cells and the corre-
sponding PSs. A pooled cDNA sample was prepared by pooling
equal amounts of individual cDNAs (1 ng), and 1 ng cDNA/PCR was
used in an initial proﬁling experiment with miRNA assays for 864
human miRNAs (miRBase v14.0) to identify miRNAs that are
expressed at detectable levels. miRNAs with a CT value of ≤32 and a
dissociation curve with peak temperature ~73–77 °C were considered
as expression positive in the analysis. In the second step, miRNAs that
showed expression in the pooled cDNA were selected for expression
analysis on individual cDNA samples. A total of 188 miRNAs were
identiﬁed as expression positive in the primary screening. We com-
pared the expressed miRNAs in PSs to the adherent non-tumor initi-
ating cell population. We investigated all miRs upregulated in PSs
with a ΔΔCT value equal to or greater than 1.8-fold normalized to
U6B and SNORA73A (Supplemental File 1). Based on the data
obtained from the qPCR-based miRNA proﬁling analysis, we deter-
mined that the following miRs had an increased expression in
PCSC1, PCSC2 and PCSC3 PSs after normalization to both U6B and
SNORA73A: miR-25*, -130a, -425, -30e, -30d, -221 and -194
(Table 1). These miRs were signiﬁcantly upregulated in comparison
to the total adherent population as they had a ΔΔCT value equal to
or greater than 1.8-fold. Additionally, the miRs we chose to further
analyze were consistently upregulated in PSs based on normalization
to both U6B and SNORA73A. Lastly, these speciﬁc miRs were of
further interest based on literature searches that had previously
identiﬁed these miRs and their potential role in tumorigenesis
(Table 2).
To further conﬁrm the overexpression of these speciﬁc miRs, we
performed qRT-PCR of the cDNA derived from individual samples of
adherent cells and PSs with the miScript primer assay corresponding
to miR-130a, miR-30e, miR-30d, miR-425, miR-221, miR-194 and
miR-25* and expression analysis was normalized to U6B. Figs. 1A–C
conﬁrm that in PSs derived from primary patient cell lines the identi-
ﬁed miRs (Table 1) are indeed overexpressed compared to the total
adherent cell population. This data in combination with the miRNA
proﬁling data demonstrates that there was a clear distinction of miRTable 1
miRNAs upregulated in primary human prostatospheres.
Using the miRNA proﬁling assay (Qiagen) we investigated all miRs upregulated in
spheres with a ΔΔCT value equal to or greater than 1.8-fold normalized to either U6B
or SNORA73.
microRNA PCSC1 PCSC2 PCSC3
25⁎ 3.09 1.57 1.64
130a 1.67 2.08 2.14
425 1.14 1.13 1.28
30e 1.45 0.83 -0.04
30d 1.62 0.96 0.12
221 1.67 2.14 0.80
194 0.87 0.81 0.97expression unique for the TIC population. After identiﬁcation and
conﬁrmation of upregulation of these speciﬁc miRs in the PS popula-
tion, we focused on the potential mRNA targets of these miRs, which
may function in maintenance of the TIC population.3.2. Identiﬁcation of mRNA targets for upregulated miRNAs
in prostatospheres
Based on our analysis of PSs in comparison to the total adherent
cell population, we have identiﬁed various upregulated miRNAs that
may function as regulators of PSs. Subsequently, we interrogated
both the miR databases Target Scan (www.targetscan.org/), a data-
base of conserved 3′ UTR miRNA targets and the miRDB (www.
mirdb.org/) for potential mRNA targets of these miRs (Supplemental
File 3). We next focused on mRNA targets previously identiﬁed in
the maintenance of stem cells or implicated in cancer development.
In particular from the list in Supplemental File 3, we speciﬁcally in-
vestigated the predicted mRNA targets of Sox, KLF, Hox, Stat, Frizzled
(FZD), Wnt and TGFB associated genes. All of these genes have been
shown to have critical functions in the regulation of cancer stem
cells [8,16].3.3. Global gene expression analysis of prostatospheres
To determine if these predicted mRNA targets were downregu-
lated in our PSs, we performed microarray analysis using Agilent's
whole genome gene expression array and identiﬁed genes that
showed a downregulation of at least 1.8-fold compared to total
cells. Of these, PCSC1 PSs had 4614 genes, PCSC2 PSs had 3484
genes and PCSCS3 PSs had 4266 genes downregulated. To gain an un-
derstanding of the genes commonly downregulated in all 3 PS popu-
lations, we identiﬁed genes that were equal to or had at least −1.8-
fold change. Using this criterion, we found a total of 180 genes that
showed downregulation among all PSs (Supplemental File 2). Based
on these 180 genes, we determined which top 10 canonical pathways
were associated with the down-regulated genes in PSs using Ingenu-
ity Pathway Analysis Software (Fig. 2A). Interestingly, the top canon-
ical pathway is the Wnt/β-catenin signaling pathway, a well
established regulator of prostate TICs (reviewed in [17,18]). The
Wnt/β-catenin signaling pathway has been established as a key regu-
lator of TICs [7,8,19] and in this speciﬁc study, the genes associated
with this pathway identiﬁed in our IPA analysis include BCL9,
MDM2, PPP2R4, PPP2R1A and TCF7L1. Additionally, IPA analysis of
downregulated genes in PSs showed association with the following
functional categories: cell death, cellular assembly and organization,
cell cycle, lipid metabolism and small molecular biochemistry
(Fig. 2B). Speciﬁcally, the processes of both cell death and cell cycle
have been intimately linked with the maintenance of TICs in an undif-
ferentiated state [8].
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Fig. 1. Identiﬁcation of upregulated miRNAs in prostatospheres.To conﬁrm overexpression of signiﬁcantly upregulated miRs identiﬁed in the miRNA proﬁling assay, we performed
qRT-PCR of the cDNA derived from individual samples of adherent cells and PSs. We used the miScript primer assay (Qiagen) corresponding to miR-130a, miR-30e, miR-30d, miR-
425, miR-194, miR-221 andmiR-25* and expression was normalized to U6B. Figs. 1A PCSC1, B: PCSC2 and C: PCSC3, conﬁrm that in PSs derived from primary patient cell lines, there
is an overexpression of the speciﬁed miRs compared to the total adherent cell population.
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Fig. 2. Global gene expression analysis of PCSC1, PCSC2 and PCSC3 prostatospheres.To elucidate the pathways associated with the commonly downregulated genes in all three
primary patient lines (PCSC1, PCSC2 and PCSC3), we compared overlapping genes and determined the top 10 canonical pathways associated with downregulation, 2A. Fig. 2B
shows the top functional categories associated with downregulation in primary patient PSs as analyzed using IPA.
111S.M. Cabarcas et al. / Genomics 99 (2012) 108–117
112 S.M. Cabarcas et al. / Genomics 99 (2012) 108–1173.4. Expression analysis of down-regulated genes in prostatospheres
To further determine which speciﬁc mRNAs may be regulated by
our identiﬁed upregulated miRs, we analyzed the expression levels
of the predicted mRNA targets (Supplemental File 3). The list of
predicted mRNA targets identiﬁed by both Target Scan and miRDB
included several mRNAs of interest and based on this list, we inter-
rogated our whole genome array data to determine if these mRNAs
were signiﬁcantly downregulated (equal to or at least −1.8 fold
change) across all primary patient PSs. Based on the upregulated ex-
pression of miR regulators, it is expected that their predicted gene
targets would be downregulated in the PS population. Among the
list of predicted mRNA targets under possible regulation by our
identiﬁed miRNAs, we identiﬁed three speciﬁc mRNAs downregu-
lated in PSs compared to the total population (Table 3): sex-
determining region Y box 4 (Sox4), Thioredoxin Interacting Protein
(TXNIP) and B-cell CLL/lymphoma 9 (BCL9). Based on the predicted
mRNA target list compiled from both Target Scan and miRDB, Sox4
is predicted to be a target of miR-25* and -130a, BCL9 is a predicted
target of miR-30d and -30e, and TXNIP is a predicted target of
miR-130a.
To further conﬁrm our whole genome array data, we analyzed
the mRNA expression of these gene targets in PSs compared to
total cells. All three PS populations have a lower expression level
of Sox4, TXNIP and BCL9 mRNA in the PSs compared to the total
adherent population, Figs. 3A–C. We then performed immunoblot
analysis to determine if protein expression of Sox4, BCL9 and
TXNIP was decreased in PSs as well. As presented in Figs. 3D–E,
for the Sox4 protein, we detected a weak decrease in PCSC3
spheres and interestingly, Sox4 protein expression was increased
in PCSC1 spheres. This is in contract with our mRNA expression
data in which Sox4 was decreased in PSs; however, Sox4 protein
and mRNA levels may not necessarily correlate due to differences
in mRNA and protein stability. However, Figs. 3D–E immunoblot
analysis shows that for both the PCSC1 and PCSC3 spheres, both
BCL9 and TXNIP were expressed at lower levels in the PSs com-
pared to the total population. Our data identiﬁes TXNIP at the
expected protein size based on the amino acid sequence
(~46 kDa) and an additional isoform of TXNIP (~55 kDa) which is
a result of posttranslational modiﬁcation as previously demon-
strated [20,21]. There are several predominate isoforms for TXNIP
that have been shown to arise from posttranslational modiﬁcation
[20]. To perform quantiﬁcation analysis, the ~46 kDa band was
used. This downregulation of both BCL9 and TXNIP is in agreement
with both the data obtained from the whole genome array and the
qRT-PCR analysis.Table 3
Gene expression of mRNA targets.
To analyze expression of the predicted mRNA targets, we utilized Agilent's whole ge-
nome array and found that BCL9, TXNIP and Sox4 were signiﬁcantly downregulated
at least 1.8 fold compared to total cells.
Upregulated
microRNAs
Cancer type Reference
25⁎ Pancreas, prostate, stomach, colorectal cancers [28,29]
130-a Angiogenesis of vascular endothelial cells; ovarian
cancer
[29–31]
425-1 Cervical cancer [32,38]
30e Ovarian, esophageal cancers [38,39]
30d Ovarian, lung squamous cell carcinoma,
hepatocellular carcinoma, medulloblastoma
[38,41–43]
221-1 Papillary thyroid carcinoma, breast, prostate
cancers
[13,28,29,34]
194-1 Esophageal, prostate, pancreatic ductal
aldenocarcinoma, squamous cell carcinoma of the
tongue
[34–37]3.5. miR inhibition results in inhibition of prostatosphere formation
Based on the miRNA proﬁling assay, we were able to identify
several miRNAs which were signiﬁcantly upregulated in our PSs
(miR-25*, 130a, 425, 30e, 30d, 221 and 194). We next sought to
investigate if inhibition of these miRNAs could affect formation of
PSs. Using the miScript miRNA Inhibitor System from Qiagen, we
transfected PCSC3 cells with the appropriate miRNA inhibitors,
seeded the transfected cells in SCMKO and analyzed and counted for
sphere formation 7 days post transfection. Fig. 4A demonstrates that
transfection of PCSC3 cells with inhibitors speciﬁc for miR-425,
-30e, -130a, -25*, -221 and -194, resulted in a statistically signiﬁcant
decrease of the number of spheres formed in comparison to the mock
transfected cells (p-valueb0.05). Additionally, Fig. 4B shows that the
miR inhibitors did not affect sphere diameter.
To ensure the inhibition of sphere formation by transfection of
miR-inhibitors was not a consequence of experimental setup or
nonspeciﬁc effects from the miR-inhibitor plasmids, using PCSC3 as
a model, we transiently transfected a miRNA inhibitor negative
control (Qiagen) which has no homology to any known mammalian
gene. Based on this experiment, there was no inhibition of sphere
formation in comparison to the cells transfected with the miRI-25*
(data not shown). Hence, we propose that inhibition of these miRs,
which we have shown to be signiﬁcantly upregulated in PSs, results
in the reduction of sphere formation ability of PCSC3 cells as a result
of a decrease in the self-renewing ability.
We further sought to investigate if the inhibition of the miRs
affected gene expression of their predicted mRNA targets, BCL9,
TXNIP and Sox4. Speciﬁcally, miR-30e is predicted to target BCL9,
miR-130a and -25* are predicted to target Sox4 and miR-130a is
predicted to target TXNIP. To further determine speciﬁcity of these
miRs to their gene targets, we used samples transfected with the
appropriate gene speciﬁc miR inhibitor and a non-targeting miR for
each target, miR-425, to assess mRNA expression levels. Based on an
mRNA target search for miR-425, Sox4, BCL9 and TXNIP do not appear
as potential targets in either Target Scan or miRDB databases, howev-
er, we show that miR-425 is capable of reducing sphere formation;
hence, we used spheres transfected with miRI-425 as a control.
Figs. 4C–E demonstrate that upon inhibition of these miRs, there is
an upregulation of gene expression of their predicted targets. The in-
hibition of miR-30e results in an increase in gene expression of BCL9,
Fig. 4C. The inhibition of miR-130-a results in an increase in TXNIP
gene expression, Fig. 4D. Fig. 4E demonstrates that upon inhibition
of miR-25* there is an increased in Sox4 expression. We speculate
that the inhibition of these miRs results in the inability to suppress
their target genes thereby resulting in the upregulation of gene
expression (Fig. 4). We propose that these genes negatively regulate
PS formation and self-renewal.
3.6. Oncomine database expression analysis
To determine if our identiﬁed mRNAs were associated with clini-
cal prognosis or outcome, we queried the Oncomine database
(http://www.oncomine.org) for the relative gene expression levels
of BCL9 and TXNIP in prostate cancer. We did not analyze Sox4 ex-
pression in the clinical database as our results demonstrated that
the protein levels did not match the mRNA levels in PSs. Using
Oncomine's outlier proﬁle analysis which identiﬁes genes with signif-
icant under-expression in a subset of cases within a given data set, we
determined that BCL9 and TXNIP are under expressed in a subset of
samples and have an association with metastasis (Fig. 5). Interesting-
ly, across 5 analyses including LaTulippe, Varambally and Yu prostate
sets including the Wooster cell line, BCL9 gene expression is signiﬁ-
cantly under expressed, p-value 5.7E-4 (Fig. 5A). Importantly, the
LaTulippe, Varambally and Yu prostate datasets represent the expres-
sion of BCL9 in metastasis compared to primary prostate sites
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Fig. 3. Expression analysis of down-regulated genes in prostatospheres.To conﬁrm the whole genome array data, we performed qRT-PCR analysis of the three predicted gene tar-
gets, Sox4, TXNIP and BCL9. qRT-PCR analysis of A: PCSC1, B: PCSC2 and C: PCSC3 spheres shows a decrease in gene expression compared to the adherent total cell population. All
data were normalized to 18S rRNA expression. To analyze protein expression of these genes, we performed immunoblot analysis for D: Sox4, E: TXNIP and F: BCL9. Actin was used
as a loading control. Quantiﬁcation analysis was performed using ImageJ Software provided by the National Institute of Health (http://rsb.info.nih.gov/ij/).
113S.M. Cabarcas et al. / Genomics 99 (2012) 108–117(Fig. 5A). Additionally, within the Yu prostate dataset, there was a
correlation of BCL9 under-expression and patients dead at 5 years in
comparison to patients alive at 5 years. Lastly, within the Wooster
CellLine dataset, there is also a lower expression of BCL9 in prostate
cancer samples. For meta-analysis of TXNIP gene expression, we com-
pared TXNIP expression in prostate carcinoma versus normal samples
in the Holzbeierlein, Liu, Magee, Vanaja and Yu prostate datasets
(Fig. 5B). We ﬁnd that in these 5 analyses, TXNIP expression is
under expressed in prostate carcinoma samples, p-value 0.017.
The meta-analysis shown in Fig. 5 demonstrates that there is in-
deed a correlation and clinical relevance between both BCL9 and
TXNIP expression in prostate carcinoma. Interestingly, these genes
showed under-expression in subsets of patient samples, speciﬁcally
in models of metastasis. The downregulation of these genes in aggres-
sive forms of prostate cancer due to the aberrant upregulation of
their miR regulators may promote maintenance of TICs resulting in
chemo- and radio-resistance thereby, contributing to metastasis and
recurrence.4. Discussion
In this study, we demonstrate that by using genome wide technol-
ogies to analyze miRNA expression in TICs we are able to correlate
aberrant miRNA expression and their effect on gene expression with-
in the TIC population. We ﬁrst analyzed miRNA expression in PSs by
using Qiagen's miRNA proﬁling array to identify upregulated miRNAs
that may function as regulators of the TIC population. After identiﬁca-
tion of signiﬁcantly upregulated miRNAs in PSs compared to total
cells, >1.8 fold (Tables 1 and 2), we explored the literature to deter-
mine if our identiﬁed miRNAs were previously shown to correlate
with cancer and if they were indeed increased by qRT-PCR (Table 2,
Fig. 1). After establishing a connection with signiﬁcantly upregulated
miRNAs and cancer, we interrogated the miRNA databases, Target
Scan and miRDB, for potential mRNA targets (Supplemental File 3).
To determine if these mRNA targets downregulated as a result of
upregulated miRNA, we used Agilent's whole genome array to ana-
lyze gene expression in PSs compared to total cell populations and
A B
BCL9
Mo
ck
m
iRI
-30
e
m
iRI
-42
5
-1
0
1
lo
g1
0R
Q
Sox4
Mo
ck
m
iRI
-13
0a
m
iRI
-25
*
m
iRI
-42
5
0
1
2
3
4
5
6
7
lo
g1
0R
Q
TXNIP
Mo
ck
m
iR
I-1
30
a
m
iR
I-4
25
0
1
2
lo
g1
0R
Q
C D E
Mo
ck
m
iR
I-4
25
m
iR
I-3
0e
m
iR
I-1
30
a
m
iR
I-2
5*
m
iR
I-2
21
m
iR
I-1
94
0
100
200
300
400
Sp
he
re
 #
Mo
ck
m
iRI
-42
5
m
iRI
-30
e
m
iRI
-13
0a
m
iRI
-25
*
m
iRI
-22
1
m
iRI
-19
4
0
50
100
150
200
Sp
he
re
  D
ia
m
et
er
 u
M
** ** ** ** ** **
Fig. 4.miR inhibition affects sphere formation and gene expression.To investigate if inhibition of upregulated miRs could affect sphere formation of PCSC3 cells, using the miScript
miRNA Inhibitor System from Qiagen, we transfected PCSC3 cells with the appropriate miRNA inhibitors, seeded the transfected cells in SCMKO and analyzed and counted for
sphere formation 7 days post transfection using GelCount (Oxford Optronix). Fig. 4A shows inhibition of sphere formation compared to the mock transfected control. Inhibition
of sphere formation by miR-inhibitors is statistically signiﬁcant, p-valueb0.05, as determined by a one-way ANOVA analysis with a Dunnett's post-test. Fig. 4B shows analysis of
sphere diameter (μM). To conﬁrm the effect of miR inhibition of gene expression, we performed qRT-PCR analysis on transfected PCSC3 cells with the appropriate miR inhibitor.
Fig. 4C shows an increase in BCL9 expression upon transfection with an inhibitor for miR-30e (miRI-30e); 4D an increase in TXNIP expression upon transfection with an
inhibitor of miR-130a (miRI-130a) and 4E shows an increase in Sox4 expression upon transfection with an inhibitor speciﬁc for miR-130a and miR-25*, respectively (miRI-130a
and miRI-25*).
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lated genes (Fig. 2). We then correlated the potential mRNA targets
with a list of signiﬁcantly downregulated genes obtained from the
Agilent array and identiﬁed 3 genes that correlated, BCL9, TXNIP
and Sox4 (Table 3) and showed that BCL9 and TXNIP had decreased
protein expression in PSs (Fig. 4). Furthermore, we demonstrated
that upon inhibition of these miRs, there is a decrease in the sphere
forming ability of PCSC3 and an upregulation of the predicted
mRNA targets, BCL9 and TXNIP (Fig. 4). Using the clinical database
Oncomine, we show evidence for the clinical signiﬁcance of loss of
BCL9 and TXNIP expression in prostate carcinoma datasets (Fig. 5).
This data demonstrates that there is a connection between aberrant
mRNA expression of both BCL9 and TXNIP and clinical outcome. Pre-
viously, Hwang et al. demonstrated there is a positive correlation
withmiRNA expression andmRNA target repression upon an increase
in cellular density [22]. In our study, we utilize an assay that enriches
for TICs in a low density population and compare miRNA expression
to an adherent population. We recognize that a limitation of our
study is the dependency on a low density assay for TIC enrichment;
however, our data demonstrates a functional role for the upregulated
miRNAs in TIC maintenance. An additional limitation of this study is
the lack of available normal controls such as normal prostate stem
cells derived from human patients. This is not unique to our labora-
tory as there is an overall lack of normal human prostate stem cells
for the prostate cancer stem cell ﬁeld. However, we are able to show
a functional role for the identiﬁed miRs in our study. We demon-
strate that inhibition of these miRs results in inhibition of PS forma-
tion and results in an upregulation of mRNA targets. This data
assigns a new role to these miRs in the ability to function in TICmaintenance and identiﬁes new gene regulators of TIC maintenance
as well.
The miRNAs identiﬁed in this study have previously been shown
to function in various cancer models. Our analysis presented evidence
that miR-25* is upregulated in PSs and has previously been shown to
be up-regulated in pancreas, prostate and stomach cancers [23] and
miR-25* is differentially regulated in models of colorectal cancers
post chemotherapy treatment [24]. miR-130a has previously been hy-
pothesized to function in metastasis and has been shown to regulate
the angiogenic phenotype of vascular endothelial cells [25]. Addition-
ally, miR-130a has been shown to be downregulated in squamous cell
lung carcinoma tissues compared with normal tissues and downregu-
lated in ovarian cancers [24,26]. miR-425 has been shown to play a
role in the regulation of cervical cancer [27,28]. miR-221 along with
miR-25 has been shown to be a member of a signature common to
various solid cancers and has been shown to be overexpressed in
tamoxifen-resistant breast cancer cells [23,24]. miR-221 is also upre-
gulated post chemotherapy treatment with cisplatin in breast cancer
[24]. Additionally, miR-221 was shown to have strong upregulation in
papillary thyroid carcinoma followed with a loss of KIT transcript and
protein expression, describing its role as an oncogene by downregula-
tion of the KIT gene [10]. Interestingly, miR-221 is signiﬁcantly down-
regulated in malignant tissue derived from prostatectomy specimens
from early relapse patients [29]. Tong et al. demonstrated that ectopic
expression of miR-221 reduced LNCaP cancer cell growth, however,
this analysis was performed on total cell populations in comparison
to our analysis performed on a sub-population isolated via prostato-
sphere formation. In the case of miR-194, elevation has been associat-
ed with Barrett's associated adenocarcinoma, a form of esophageal
4. Prostate Cancer - Metastasis
Yu Prostate, J Clin Oncol, 2004
5. Prostate Carcinoma - Dead at 5 Years
Yu Prostate, J Clin Oncol, 2004
1. Prostate Cancer - Metastasis
LaTulippe Prostate, Cancer Res, 2002
2. Prostate Cancer - Metastasis
Varambally Prostate, Cancer Cell, 2005
3. Cancer Type: Prostate Cancer
Wooster CellLine, Not Published, 2008
BCL9 Metastasis AnalysisA
TXNIP Expression Analysis in Prostate Carcinoma vs Normal
1. Prostate Carcinoma vs. Normal
Holzbeierlein Prostate, Am J Pathol, 2004
2. Prostate Carcinoma vs. Normal
Liu Prostate, Cancer Res, 2006
3. Prostate Carcinoma vs. Normal
Magee Prostate, Cancer Res, 2001
4. Prostate Adenocarcinoma vs. Normal
Vanaja Prostate, Cancer Res, 2003
5. Prostate Carcinoma vs. Normal
Yu Prostate, J Clin Oncol, 2004
B
Fig. 5. Oncomine database expression analysis.To determine if downregulation of BCL9 and TXNIP had clinical signiﬁcance, we utilized the Oncomine database ((http://www.
oncomine.org). Fig. 5A shows that BCL9 is signiﬁcantly downregulated in prostate carcinoma studies associated with metastasis. Fig. 5B demonstrates that TXNIP is signiﬁcantly
downregulated in various prostate carcinoma studies.
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in a highly metastatic group [31] and downregulation has been seen
in squamous cell carcinoma of the tongue [32]. Lastly, miRs-30e and
-30d have been shown to have an association with ovarian cancer
[33]. miR-30e has also been implicated in esophageal cancer develop-
ment and has been hypothesized to possibly serve as a useful predic-
tive marker in patients with esophageal adenocarcinoma [34]. miR-30e
is differentially regulated in multiple primary and metastatic cancers
demonstrating its involvement in the process of metastasis [35]. miR-
30d is downregulated in lung squamous cell carcinoma compared to
normal lung tissue [36] and upregulated in hepatocellular carcinoma
and associated with promotion of cell migration and invasion [37].
There is additional evidence suggesting that miR-30d functions as an
oncogene in medulloblastoma as well [38]. All upregulated miRs and
associated cancer types are summarized in Table 2.
The Sox4 transcription factor is a developmental transcription
factor belonging to the Sox protein family involved in development.
Additional roles of Sox4 include the regulation of progenitor develop-
ment andWnt signaling although the exact role it plays is still unclear
[39]. Sox4 is speculated to play a role in early differentiation, develop-
mental pathways and metastasis (reviewed in [39]). In contrast to its
family member and known TIC regulator, SOX2, Sox4 is not a stem
cell marker. Additional Sox family members such as Sox5 have been
shown to correlate with prevention of terminal differentiation in
neural progenitors via interference with the Wnt-β-catenin
(CTNNB1) pathway [40] and Sox1 has been shown to function as a
regulator and promoter of neuronal differentiation [41]. It is sug-
gested that Sox4 plays a role in early differentiation, can contributeto the expansion of transit amplifying progenitor cells and can func-
tion as a promoter of metastasis and tissue invasion by inhibiting ter-
minal differentiation (reviewed in [39]). Sox4 is often overexpressed
in variety of cancers including prostate, bladder and lung cancers as
well as leukemias, melanomas and glioblastomas [39]. In bladder car-
cinoma, Sox4 cytoplasmic staining in patient samples has been shown
to correlate with an increased patient survival and its increased ex-
pression is a result of its pro-apoptotic function [42]. Sox4 can inter-
act with various developmental pathways implicated in TIC
maintenance such as the Notch, Wnt and PI3K/AKT pathways as
well [39]. To date, the exact mechanism(s) and role Sox4 plays in
prostate cancer is unknown and appears to vary based on Sox4 regu-
lation mechanism(s). However, it is possible to speculate that Sox4
overexpression is observed in various cancers due to the bulk tumor
containing a heterogeneous population mainly consisting of actively
proliferating cells, therefore, Sox4 is needed to maintain aberrant pro-
liferation. This speciﬁc role of Sox4 in combination with its ability to
function as a pro-apoptotic regulator and its ability to interact with
crucial development pathways demonstrates how critical the regula-
tion of Sox4 is for proper cellular maintenance.
We have identiﬁed Sox4 mRNA as being downregulated in PSs
compared to the total cell population and in addition to this, we ob-
served that the Sox4 protein and mRNA levels do not correlate.
Sox4 protein has been shown to form a protein complex with other
proteins such as syndecan binding protein, syntenin (SDCBP), a pro-
tein which functions in cytoskeletal-membrane organization, cell ad-
hesion, protein trafﬁcking and transcription factor activation [43].
Syntenin has been shown to bind to Delta1 (DLK1), the Notch ligand,
116 S.M. Cabarcas et al. / Genomics 99 (2012) 108–117which has been shown to promote stem cell clustering in epidermal
cells. Syntenin has also been shown to be upregulated in stem cell
clusters of human interfollicular epidermis [44]. Therefore, we believe
it is plausible to speculate that Sox4 protein expression may be upre-
gulated in our PSs in contrast to the observed downregulated mRNA
expression due to its stabilization with a protein complex that func-
tions to promote stem cell clustering, hence, promoting PS formation.
We speculate however that the downregulation of Sox4 mRNA in this
speciﬁc population of cells is a result of the upregulation of miRs
which control Sox4 expression, miR-25* and -130a-1. We hypothe-
size that it is beneﬁcial to PSs, which represent a quiescent population
of slow cycling TICs, to down-regulate Sox4 in maintaining an undif-
ferentiated state as Sox4 expression is associated with early differen-
tiation and functions as a contributor to transit amplifying progenitor
cells. Additionally, as Sox4 has been shown to have a role in pro-
apoptotic mechanisms, it is possible to hypothesize that loss of Sox4
expression in PSs contributes to their anti-apoptotic characteristics
as demonstrated by their ability to resist radio- and chemo-
therapeutic treatments hence, contributing to metastasis and reoc-
currence. As stated, other Sox family members have also been
shown to play a role in promotion of differentiation and regulation
of cell cycle progression, therefore, it is possible that Sox4 regulates
these processes as well in the TIC population, possibly via Wnt-β-
catenin signaling as previously observed for other Sox family mem-
bers [40,41].
BCL9 has recently been shown to play a role in the transcriptional
activity of β-catenin in association with LEF/TCF family members [45].
BCL9 expression favors an epithelial-to-mesenchymal transition
(EMT)-like differentiation of tumor cells by enhancing β-catenin me-
diated transcriptional activity in models dependent or independent of
Wnt signaling mutational status [46]. It is established that β-catenin
plays a role in maintaining self-renewal of TIC populations [7] and
homozygous deletion of BCL9 in mice shows that the Wnt-mediated
transduction of proliferative signals remain unaffected by loss of
Bcl9 expression [47]. It has also been shown that BCL9 knockdown
in both multiple myeloma and colon carcinoma cells decreases cell
cycle progression without affecting cellular survival under stress con-
ditions [46]. We demonstrate here that there is a loss of BCL9 expres-
sion in our PSs and hypothesize that this is a result of the
upregulation of miRNAs predicted to control BCL9 expression such
as miR-30d and -30e. We speculate that in our PSs, the loss of BCL9
results in the loss of the ability of the Wnt-signaling pathway to pro-
mote differentiation thereby, allowing the maintenance of an undif-
ferentiated state. Additionally, we propose that loss of BCL9
contributes to the slow cell cycling phenotype that quiescent cancer
stem cells are often characterized by (reviewed in [48]). The ability
of TICs to undergo slow cycling allows this unique population to de-
velop resistance and functions in reoccurrence therefore, lending a
survival advantage to this population.
TXNIP, also known as VDUP1, is a mediator of oxidative stress and
is a negative regulator of thioredoxin (TXN), a redox protein with a
role in reactive oxygen species (ROS) response and cell to cell com-
munication that has been implicated in playing an important role in
human disease. TXNIP was ﬁrst identiﬁed as a gene up-regulated in
response to vitamin D3/calcitriol exposure and later identiﬁed as a
tumor suppressor [49]. TXNIP has been shown to function as an
anti-metastatic in melanoma cells when overexpressed [50] and has
also been shown to play a role in renal carcinogenesis [51] and pros-
tate carcinoma [52]. Additionally, TXNIP plays a role in hematopoietic
stem cell (HSC) quiescence and mobilization under stress conditions
[53]. Most importantly, TXNIP loss results in an increased ability to
mobilize to secondary hematopoietic organs [53]. This in combination
with our data showing a loss of TXNIP expression in PSs leads us to
believe that loss of TXNIP in PSs results in a blockade of differentiation
and may possibly lead to increased metastasis, a feature often as-
cribed to TICs. TXNIP downregulation in PSs is a novel ﬁnding andfurther analysismust be performed to elucidate the exactmechanism(s)
TXNIP plays in PSs maintenance.
5. Conclusions
In this study, we established a connection between miRNA upre-
gulation and mRNA downregulation in PSs, a population enriched
for TICs. It is necessary to further investigate the processes which
govern the ability of a TIC to maintain its ability to self-renew and dif-
ferentiate. This study gives a unique perspective into genes downre-
gulated in PSs which are most likely under the control of the
identiﬁed miRs. Furthermore, this study gives further insight into to
the mechanism(s) which may contribute to the development and
maintenance of TICs thereby, possibly revealing targets that may be
signiﬁcant in the development of potential therapeutic targets.
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.ygeno.2011.11.007.
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